Viral Phenotypic Resistance Assays

  • Neil Parkin
Part of the Infectious Disease book series (ID)

Phenotypic susceptibility assays are used for some viruses in a clinical setting, i.e., to help construct the most active drug regimen for an individual patient’s virus. They are also employed in research studies to establish correlations between discrete genotypic changes and drug susceptibility, and in the characterization of cross-resistance patterns for new drugs in pre-clinical and clinical stages of development.


Human Immunodeficiency Virus Type Antimicrob Agent Recombinant Virus Drug Susceptibility Susceptibility Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    d'Herelle F, Smith GH. The Bacteriophage and its Behavior. Baltimore, MD: Williams & Wilkins; 1926.Google Scholar
  2. 2.
    Dulbecco R, Vogt M. Some problems of animal virology as studied by the plaque technique. Cold Spring Harb Symp Quant Biol 1953;18:273–9.PubMedGoogle Scholar
  3. 3.
    Dulbecco R, Vogt M. Plaque formation and isolation of pure lines with poliomyelitis viruses. J Exp Med 1954;99(2):167–82.PubMedGoogle Scholar
  4. 4.
    Dulbecco R, Vogt M. Biological properties of poliomyelitis viruses as studied by the plaque technique. Ann N Y Acad Sci 1955;61(4):790–800.PubMedGoogle Scholar
  5. 5.
    Sidwell RW, Smee DF. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res 2000;48(1):1–16.PubMedGoogle Scholar
  6. 6.
    Christophers J, Clayton J, Craske J, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998;42(4):868–72.PubMedGoogle Scholar
  7. 7.
    Landry ML, Stanat S, Biron K, et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 2000;44(3):688–92.PubMedGoogle Scholar
  8. 8.
    Biron KK, Fyfe JA, Noblin JE, Elion GB. Selection and preliminary characterization of acyclovir-resistant mutants of varicella zoster virus. Am J Med 1982;73(1A):383–6.PubMedGoogle Scholar
  9. 9.
    Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to Zidovudine (AZT) isolated during prolonged therapy. Science 1989;243(March 31):1731–4.PubMedGoogle Scholar
  10. 10.
    Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006;37(2):124–7.PubMedGoogle Scholar
  11. 11.
    Bacon TH, Howard BA, Spender LC, Boyd MR. Activity of penciclovir in antiviral assays against herpes simplex virus. J Antimicrob Chemother 1996;37(2):303–13.PubMedGoogle Scholar
  12. 12.
    Prichard MN, Turk SR, Coleman LA, Engelhardt SL, Shipman C, Jr., Drach JC. A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J Virol Methods 1990;28(1):101–6.PubMedGoogle Scholar
  13. 13.
    Leary JJ, Wittrock R, Sarisky RT, Weinberg A, Levin MJ. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob Agents Chemother 2002;46(3):762–8.PubMedGoogle Scholar
  14. 14.
    McSharry JJ, McDonough AC, Olson BA, Drusano GL. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors. Clin Diagn Lab Immunol 2004;11(1):21–8.PubMedGoogle Scholar
  15. 15.
    Dankner WM, Scholl D, Stanat SC, Martin M, Sonke RL, Spector SA. Rapid antiviral DNA—DNA hybridization assay for human cytomegalovirus. J Virol Methods 1990;28(3):293–8.PubMedGoogle Scholar
  16. 16.
    Chesebro B, Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol 1988;62(10):3779–88.PubMedGoogle Scholar
  17. 17.
    Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992;66(4):2232–9.PubMedGoogle Scholar
  18. 18.
    Vodicka MA, Goh WC, Wu LI, et al. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 1997;233(1):193–8.PubMedGoogle Scholar
  19. 19.
    Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993;37(5):1095–101.PubMedGoogle Scholar
  20. 20.
    Kellam P, Larder BA. Recombinant virus assay: a rapid, pheno-typic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994;38(1):23–30.PubMedGoogle Scholar
  21. 21.
    Boucher CAB, Keulen W, Van Bommel T, et al. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996;40(10):2404–9.PubMedGoogle Scholar
  22. 22.
    Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20(4):309–21.PubMedGoogle Scholar
  23. 23.
    Hertogs K, De Béthune M-P, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42(2):269–76.PubMedGoogle Scholar
  24. 24.
    Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999;13(15):2061–8.PubMedGoogle Scholar
  25. 25.
    Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44(4):920–8.PubMedGoogle Scholar
  26. 26.
    Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296(7):827–43.PubMedGoogle Scholar
  27. 27.
    Qari SH, Respess R, Weinstock H, et al. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol 2002; 40(1):31–5.PubMedGoogle Scholar
  28. 28.
    Miller V, Schuurman R, Clavel F, et al. Comparison of HIV-1 drug susceptibility (phenotype) results reported by three major laboratories. Antivir Ther 2001;6(suppl 1):S129.Google Scholar
  29. 29.
    Zhang J, Rhee SY, Taylor J, Shafer RW. Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays. J Acquir Immune Defic Syndr 2005;38(4):439–44.PubMedGoogle Scholar
  30. 30.
    Lanier ER, Hellmann N, Scott J. Determination of a clinically relevant phenotypic resistance “cutoff” for abacavir using the PhenoSense assay. In: 8th Conference on Retroviruses and Opportunistic Infections, 2001 February, Chicago, IL; 2001.Google Scholar
  31. 31.
    Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virologic response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 2002;7(3):165–74.PubMedGoogle Scholar
  32. 32.
    Skowron G, Whitcomb J, Wesley M, et al. Viral load response to the addition of lamivudine correlates with phenotypic susceptibility to lamivudine and the presence of T215Y/F in the absence of M184V. Antivir Ther 1999;4(suppl 1):55–6.Google Scholar
  33. 33.
    Szumiloski J, Wilson H, Jensen E, et al. Relationships between indinavir resistance and virological responses to indinavir- ritonavir-containing regimens in patients with previous protease inhibitor failure. Antivir Ther 2002;7(suppl 1):S127.Google Scholar
  34. 34.
    Flandre P, Chappey C, Marcelin AG, et al. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection. J Infect Dis 2007;195(3):392–8.PubMedGoogle Scholar
  35. 35.
    Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004;189(5):837–46.PubMedGoogle Scholar
  36. 36.
    Coakley EP, Chappey C, Flandre P, et al. Defining lower (L) and upper (U) phenotypic clinical cutoffs (CCO's) for tipranavir (TPV), lopinavir (LPV), saquinavir (SQV) and amprenavir (APV) co-administered with ritonavir (r) within the RESIST Dataset using the PhenoSense Assay. Antivir Ther 2006;11:S81.Google Scholar
  37. 37.
    Coakley EP, Chappey C, Maa JF, et al. Determination of pheno-typic clinical cutoffs for atazanavir and atazanavir/ritonavir from AI424-043 and AI424-045. Antivir Ther 2005;10:S8.Google Scholar
  38. 38.
    Coakley EP, Chappey C, Benhamida J, Picchio G, de Béthune M-P. Defining the Upper and Lower Phenotypic Clinical CutOffs for Darunavir/r (DRV/r) by the PhenoSense Assay. In: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA; 2007.Google Scholar
  39. 39.
    Dam E, Obry V, Lecoeur H, et al. Definition of clinically relevant cut-offs for the interpretation of phenotypic data obtained using Phenoscript. Antivir Ther 2001;6(suppl 1):123.Google Scholar
  40. 40.
    Lanier ER, Ait-Khaled M, Scott J, et al. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir Ther 2004;9(1):37–45.PubMedGoogle Scholar
  41. 41.
    Verlinden Y, Vermeiren H, Lecocq P, et al. Assessment of the Antivirogram performance over time including a revised definition of biological test cut-off values. Antivir Ther 2005;10:S51.Google Scholar
  42. 42.
    Borroto-Esoda K, Miller M, Petropoulos CJ, Parkin N. A Comparison of the Phenotypic Profiles of Emtricitabine (FTC) and Lamivudine (3TC). In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapeutics, 2004 October 30 – November 2, Washington, DC; 2004.Google Scholar
  43. 43.
    Haubrich R, Keiser P, Kemper C, et al. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antivir Ther 2001; 6(suppl 1):63.Google Scholar
  44. 44.
    Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wildtype human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48(2):437–43.PubMedGoogle Scholar
  45. 45.
    De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3. Antivir Ther 2006;11:S83.Google Scholar
  46. 46.
    Naeger LK, Struble KA. Food and Drug administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 2007;21(2):179–85.PubMedGoogle Scholar
  47. 47.
    Harrigan PR, Montaner JS, Wegner SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001;15(13):1671–7.PubMedGoogle Scholar
  48. 48.
    Greenberg M, Cammack N, Salgo M, Smiley L. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol 2004;14(5):321–37.PubMedGoogle Scholar
  49. 49.
    Marcelin AG, Reynes J, Yerly S, et al. Characterization of geno-typic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS 2004;18(9):1340–2.PubMedGoogle Scholar
  50. 50.
    Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46(6):1896–905.PubMedGoogle Scholar
  51. 51.
    Zollner B, Feucht HH, Schroter M, et al. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS 2001;15(7):935–6.PubMedGoogle Scholar
  52. 52.
    Lu J, Kuritzkes DR. A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants. J Acquir Immune Defic Syndr 2001;27(1):7–13.PubMedGoogle Scholar
  53. 53.
    Resch W, Parkin N, Stuelke EL, Watkins T, Swanstrom R. A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. Proc Natl Acad Sci U S A 2001;98(1):176–81.PubMedGoogle Scholar
  54. 54.
    Grant RM, Liegler T, Elkin C, et al. Protease Inhibitor Resistant HIV-1 Has Marked Decreased Fitness In Vivo. In: 8th Conference on Retroviruses and Opportunistic Infections, 2001 February, Chicago, IL; 2001.Google Scholar
  55. 55.
    Barbour JD, Hecht FM, Wrin T, et al. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 2004;190(2):251–6.PubMedGoogle Scholar
  56. 56.
    Bates M, Chappey C, Parkin N. Mutations in p6 Gag Associated with Alterations in Replication Capacity in Drug Sensitive HIV-1 Are Implicated in the Budding Process Mediated by TSG101 and AIP1. In: 11th Conference on Retroviruses and Opportunistic Infections, 2004 February 8–11, San Francisco, CA; 2004.Google Scholar
  57. 57.
    Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344(7):472–80.PubMedGoogle Scholar
  58. 58.
    Gandhi RT, Wurcel A, Rosenberg ES, et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003;37(12):1693–8.PubMedGoogle Scholar
  59. 59.
    Masquelier B, Capdepont S, Neau D, et al. Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy. AIDS 2007;21(1):103–6.PubMedGoogle Scholar
  60. 60.
    Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004;18(12):1683–9.PubMedGoogle Scholar
  61. 61.
    van Maarseveen NM, Wensing AM, de Jong D, et al. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis 2007;195(3):399–409.PubMedGoogle Scholar
  62. 62.
    Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999;73(5):3744–52.PubMedGoogle Scholar
  63. 63.
    Prado JG, Wrin T, Beauchaine J, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002;16(7):1009–17.PubMedGoogle Scholar
  64. 64.
    Maguire MF, Guinea R, Griffin P, et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002;76(15):7398–406.PubMedGoogle Scholar
  65. 65.
    Ziermann R, Limoli K, Das K, Arnold E, Petropoulos CJ, Parkin NT. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol 2000;74(9):4414–9.PubMedGoogle Scholar
  66. 66.
    Resch W, Ziermann R, Parkin N, Gamarnik A, Swanstrom R. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J Virol 2002;76(17):8659–66.PubMedGoogle Scholar
  67. 67.
    Deval J, White KL, Miller MD, et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004; 279(1):509–516.PubMedGoogle Scholar
  68. 68.
    White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002;46(11):3437–46.PubMedGoogle Scholar
  69. 69.
    Huang W, Gamarnik A, Limoli K, Petropoulos CJ, Whitcomb JM. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol 2003;77(2):1512–23.PubMedGoogle Scholar
  70. 70.
    Sufka SA, Ferrari G, Gryszowka VE, et al. Prolonged CD4+ cell/ virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infect Dis 2003;187(7):1027–37.PubMedGoogle Scholar
  71. 71.
    Campbell TB, Schneider K, Wrin T, Petropoulos CJ, Connick E. Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J Virol 2003;77(22):12105–12.PubMedGoogle Scholar
  72. 72.
    Moser B. Chemokines and HIV: a remarkable synergism. Trends Microbiol 1997;5(3):88–90.PubMedGoogle Scholar
  73. 73.
    Collin M, Illei P, James W, Gordon S. Definition of the range and distribution of human immunodeficiency virus macrophage tropism using PCR-based infectivity measurements. J Gen Virol 1994;75 (Pt 7):1597–603.PubMedGoogle Scholar
  74. 74.
    Tersmette M, de Goede RE, Al BJ, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988;62(6):2026–32.PubMedGoogle Scholar
  75. 75.
    Fenyo EM, Morfeldt-Manson L, Chiodi F, et al. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988;62(11):4414–9.PubMedGoogle Scholar
  76. 76.
    Asjo B, Morfeldt-Manson L, Albert J, et al. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986;2(8508):660–2.PubMedGoogle Scholar
  77. 77.
    McKnight A, Wilkinson D, Simmons G, et al. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol 1997;71(2):1692–6.PubMedGoogle Scholar
  78. 78.
    Chen Z, Zhou P, Ho DD, Landau NR, Marx PA. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol 1997;71(4):2705–14.PubMedGoogle Scholar
  79. 79.
    Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272(5270):1955–8.PubMedGoogle Scholar
  80. 80.
    Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381(6584):667–73.PubMedGoogle Scholar
  81. 81.
    Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85(7):1149–58.PubMedGoogle Scholar
  82. 82.
    Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381(6584):661–6.PubMedGoogle Scholar
  83. 83.
    Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85(7):1135–48.PubMedGoogle Scholar
  84. 84.
    Schols D. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res 2006;71(2–3):216–26.PubMedGoogle Scholar
  85. 85.
    The ACTG Virology Technical Advisory Committee and the Division of AIDS National Institute of Allergy and Infectious Diseases. The ACTG Virology Manual for HIV laboratories; 1997. Report No. NIH-97-3828.Google Scholar
  86. 86.
    Koot M, Vo s AH, Keet RP, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultiva-tion assay. AIDS 1992;6(1):49–54.PubMedGoogle Scholar
  87. 87.
    Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syn-cytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993;118(9):681–8.PubMedGoogle Scholar
  88. 88.
    Trouplin V, Salvatori F, Cappello F, et al. Determination of core-ceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001;75(1):251–9.PubMedGoogle Scholar
  89. 89.
    Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51(2):566–75.PubMedGoogle Scholar
  90. 90.
    Skrabal K, Low AJ, Dong W, et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol 2007;45(2):279–84.PubMedGoogle Scholar
  91. 91.
    Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharma-cokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37(2):1253–62.PubMedGoogle Scholar
  92. 92.
    Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV Type 1 Chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007;44(4):591–5.PubMedGoogle Scholar
  93. 93.
    Hosoya N, Su Z, Wilkin T, et al. Assessing HIV-1 Tropism in ACTG 5211: A comparison of Assays Using Replication Competent Virus from Peripheral Blood Mononuclear Cells Versus Plasma-Derived Pseudotyped Virions. In: 2nd International Workshop Targeting HIV Entry, Boston, USA; 2006.Google Scholar
  94. 94.
    Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006;44(3):593–606.PubMedGoogle Scholar
  95. 95.
    Ladner SK, Miller TJ, King RW. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob Agents Chemother 1998;42(8):2128–31.PubMedGoogle Scholar
  96. 96.
    Chin R, Shaw T, Torresi J, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-d-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-l-arabinofuranosyluracil. Antimicrob Agents Chemother 2001;45(9):2495–501.PubMedGoogle Scholar
  97. 97.
    Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995;69(9):5437–44.PubMedGoogle Scholar
  98. 98.
    Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 2006;26(2):171–80.PubMedGoogle Scholar
  99. 99.
    Durantel D, Brunelle MN, Gros E, et al. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol 2005;34(suppl 1):S34–43.PubMedGoogle Scholar
  100. 100.
    Yang H, Westland C, Xiong S, Delaney WE. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res 2004;61(1):27–36.PubMedGoogle Scholar
  101. 101.
    Barraud L, Durantel S, Ollivet A, et al. Development of a new high throughput phenotyping test to evaluate the drug susceptibility of HBV strains isolated from patients: Phenoscript-HBV. Antivir Ther 2006;11:S9.Google Scholar
  102. 102.
    Delaney WE, Miller TG, Isom HC. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother 1999;43(8):2017–26.PubMedGoogle Scholar
  103. 103.
    Delaney WE, Edwards R, Colledge D, et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001;45(6):1705–13.PubMedGoogle Scholar
  104. 104.
    Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345(20):1452–7.PubMedGoogle Scholar
  105. 105.
    Manns MP, Cornberg M, Wedemeyer H. Current and future treatment of hepatitis C. Indian J Gastroenterol 2001;20(suppl 1): C47–51.PubMedGoogle Scholar
  106. 106.
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958–65.PubMedGoogle Scholar
  107. 107.
    De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005;436(7053):953–60.PubMedGoogle Scholar
  108. 108.
    Neyts J. Selective inhibitors of hepatitis C virus replication. Antiviral Res 2006;71(2–3):363–71.PubMedGoogle Scholar
  109. 109.
    Cabot B, Martell M, Esteban JI, et al. Longitudinal evaluation of the structure of replicating and circulating hepatitis C virus qua-sispecies in nonprogressive chronic hepatitis C patients. J Virol 2001;75(24):12005–13.PubMedGoogle Scholar
  110. 110.
    Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992;66(5):3225–9.PubMedGoogle Scholar
  111. 111.
    Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282(5386):103–7.PubMedGoogle Scholar
  112. 112.
    Steinhauer DA, Holland JJ. Rapid evolution of RNA viruses. Annu Rev Microbiol 1987;41:409–33.PubMedGoogle Scholar
  113. 113.
    Lohmann V, Korner F, Koch J-O, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285(5424):110–3.PubMedGoogle Scholar
  114. 114.
    Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000;290(5498):1972–5.PubMedGoogle Scholar
  115. 115.
    Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001;75(10):4614–24.PubMedGoogle Scholar
  116. 116.
    Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001;75(3):1437–49.PubMedGoogle Scholar
  117. 117.
    Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002;76(24):13001–14.PubMedGoogle Scholar
  118. 118.
    Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002;76(6):2997–3006.PubMedGoogle Scholar
  119. 119.
    Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003;77(5):3181–90.PubMedGoogle Scholar
  120. 120.
    Gu B, Gates AT, Isken O, Behrens SE, Sarisky RT. Replication studies using genotype 1a subgenomic hepatitis C virus replicons. J Virol 2003;77(9):5352–9.PubMedGoogle Scholar
  121. 121.
    Kato T, Date T, Miyamoto M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenter-ology 2003;125(6):1808–17.Google Scholar
  122. 122.
    Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11(7):791–6.PubMedGoogle Scholar
  123. 123.
    Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005;102(26):9294–9.PubMedGoogle Scholar
  124. 124.
    Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309(5734):623–6.PubMedGoogle Scholar
  125. 125.
    Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004;279(17):17508–14.PubMedGoogle Scholar
  126. 126.
    Lu L, Pilot-Matias TJ, Stewart KD, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004;48(6):2260–6.PubMedGoogle Scholar
  127. 127.
    Trozzi C, Bartholomew L, Ceccacci A, et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003;77(6):3669–79.PubMedGoogle Scholar
  128. 128.
    Nguyen TT, Gates AT, Gutshall LL, et al. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothia-diazine inhibitor. Antimicrob Agents Chemother 2003;47(11):3525–30.PubMedGoogle Scholar
  129. 129.
    Migliaccio G, Tomassini JE, Carroll SS, et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 2003;278(49):49164–70.PubMedGoogle Scholar
  130. 130.
    Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 28–38.Google Scholar
  131. 131.
    Yi M, Tong X, Skelton A, et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor: reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006; 281(12):8205–8215.PubMedGoogle Scholar
  132. 132.
    Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005;280(44):36784–91.PubMedGoogle Scholar
  133. 133.
    Le Pogam S, Kang H, Harris SF, et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 2006;80(12):6146–54.PubMedGoogle Scholar
  134. 134.
    Le Pogam S, Jiang WR, Leveque V, et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 2006;351:349–359.PubMedGoogle Scholar
  135. 135.
    Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 2005;49(10):4305–14.PubMedGoogle Scholar
  136. 136.
    Kukolj G, McGibbon GA, McKercher G, et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 2005;280(47):39260–7.PubMedGoogle Scholar
  137. 137.
    Tomei L, Altamura S, Paonessa G, De Francesco R, Migliaccio G. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antiviral Chem Chemother 2005;16(4):225–45.Google Scholar
  138. 138.
    Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767–1777.PubMedGoogle Scholar
  139. 139.
    Ludmerer SW, Graham DJ, Boots E, et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005;49(5):2059–69.PubMedGoogle Scholar
  140. 140.
    Tripathi RL, Krishnan P, He Y, et al. Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera. Antiviral Res 2007;73(1):40–9.PubMedGoogle Scholar
  141. 141.
    Penuel E, Han D, Favero K, Lam E, Liu Y, Parkin NT. Development of a rapid phenotypic susceptibility assay for HCV polymerase inhibitors. Antivir Ther 2006;11:S12.Google Scholar
  142. 142.
    Morfin F, Thouvenot D, De Turenne-Tessier M, Lina B, Aymard M, Ooka T. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 1999;43(10):2412–6.PubMedGoogle Scholar
  143. 143.
    Bestman-Smith J, Boivin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol 2003;77(14):7820–9.PubMedGoogle Scholar
  144. 144.
    Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganci-clovir. J Infect Dis 2002;185(2):162–9.PubMedGoogle Scholar
  145. 145.
    Kemble G, Duke G, Winter R, Spaete R. Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J Virol 1996;70(3):2044–8.PubMedGoogle Scholar
  146. 146.
    Chou S, Van Wechel LC, Lichy HM, Marousek GI. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005;49(7):2710–5.PubMedGoogle Scholar
  147. 147.
    Jabs DA, Martin BK, Forman MS, et al. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2001;183(2):333–7.PubMedGoogle Scholar
  148. 148.
    Weinberg A, Leary JJ, Sarisky RT, Levin MJ. Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues. J Clin Virol 2007;38(2):139–45.PubMedGoogle Scholar
  149. 149.
    Hayden FG, Cote KM, Douglas RG, Jr. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother 1980;17(5):865–70.PubMedGoogle Scholar
  150. 150.
    Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. Fluorometric assay of neuraminidase with a sodium (4-methylum-belliferyl-alpha-d-N-acetylneuraminate) substrate. Anal Biochem 1979;94(2):287–96.PubMedGoogle Scholar
  151. 151.
    McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003;47(7):2264–72.PubMedGoogle Scholar
  152. 152.
    Smee DF, Sidwell RW, Morrison AC, et al. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201. Antiviral Res 2001;52(3):251–9.PubMedGoogle Scholar
  153. 153.
    Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001;183(4):523–31.PubMedGoogle Scholar
  154. 154.
    Blick TJ, Sahasrabudhe A, McDonald M, et al. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology 1998;246(1):95–103.PubMedGoogle Scholar
  155. 155.
    Bantia S, Ghate AA, Ananth SL, Babu YS, Air GM, Walsh GM. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. Antimicrob Agents Chemother 1998;42(4):801–7.PubMedGoogle Scholar
  156. 156.
    Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006;50(7):2395–402.PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Neil Parkin
    • 1
  1. 1.Monogram BiosciencesSouth San FranciscoUSA

Personalised recommendations